Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

NCT01815840

CompletedPhase 2

Sponsor: Hoffmann-La Roche

Conditions: Basal Cell Carcinoma

Interventions: Vismodegib, Placebo

Countries: United States, Austria, Canada, France, Germany, Italy, Mexico, Netherlands

This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma. Participants will receive vismodegib 150 mg orally once daily either in an intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo (Arm A) or as 24 weeks induction followed by an intermittent schedule of 8 weeks placebo followed by 8 weeks vismodegib (Arm B). Anticipated time on study treatment is 72 weeks.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adult participants, \>/= 18 years of age
* Participants with multiple basal cell carcinomas, including participants with Gorlin syndrome, with at least 6 clinically evident basal cell carcinomas at the time of randomization, of which 3 measure 5 mm or more in diameter and are considered target lesions. All other lesions are considered to be non-target lesions
* Histopathologic confirmation that at least one of the three target lesions is basal cell carcinoma
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Adequate renal and hepatic function and hematopoietic capacity
* Women of childbearing potential must agree to use contraception as defined by protocol during treatment and for at least 9 months after completion of study treatment
* Male participants with female partners of childbearing potential must agree to use contraception as defined by protocol during treatment and for 2 months after completion of study treatment

Exclusion Criteria:

* Inability or unwillingness to swallow capsules
* Pregnant or breastfeeding women
* Any metastatic basal cell carcinoma
* Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to have medical contraindications to surgery
* Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study
* Known or suspected alcohol abuse
* One of the following known rare hereditary conditions: galactose intolerance, primary hypolactasia or glucose-galactose malabsorption
Locations (58)
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • San Diego, California, United States
  • Santa Rosa, California, United States
  • Ormond Beach, Florida, United States
  • Plantation, Florida, United States
  • Atlanta, Georgia, United States
  • Carmel, Indiana, United States
  • Beverly, Massachusetts, United States
  • St Louis, Missouri, United States
  • St Louis, Missouri, United States
  • Smithtown, New York, United States
  • West Islip, New York, United States
  • Winston-Salem, North Carolina, United States
  • Columbus, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Innsbruck, Austria
  • Vienna, Austria
  • Vancouver, British Columbia, Canada
  • Burlington, Ontario, Canada
  • Montreal, Quebec, Canada
  • Amiens, France
  • Bordeaux, France
  • Dijon, France
  • Limoges, France
  • Marseille, France
  • Montpellier, France
  • Nantes, France
  • Paris, France
  • + 28 more on CT.gov